Feeding administration of daikenchuto suppresses colitis induced by naive CD4+ T cell transfer into SCID mice

tsutomu iwasa, Haruei Ogino, Kazuhiko Nakamura, Eikichi Ihara, Hirotada Akiho, Ryoichi Takayanagi

研究成果: ジャーナルへの寄稿記事

9 引用 (Scopus)

抄録

Background and Aims Daikenchuto, a traditional Japanese herbal medicine, suppresses bacterial translocation by improvement of gastrointestinal motility and blood flow. As Daikenchuto reportedly reduces gastrointestinal inflammatory activity by these mechanisms, we analyzed whether Daikenchuto suppresses experimental colitis and reduces inflammatory cytokine expression in a mouse model. Methods Colitis was induced by transfer of naive CD4+ T cells of BALB/c mice into SCID mice, and mice were given either control or 2.7 % Daikenchuto-containing feed. We investigated body weight, clinical symptoms, histological changes, and Th1- and Th17-cytokine expression. Cytokine mRNA expression was analyzed using real-time RT-PCR. The ratio of IL-17+ and IFN-c+ CD4+ T cells were analyzed by flow cytometry. Results Daikenchuto delayed the development of colitis and significantly reduced the histological inflammation scores. Analyses of cytokine mRNA revealed that Th17 cytokines were significantly decreased in colons of mice that received Daikenchuto. Absolute numbers of IL-17+ or IFN-c+ CD4+ T cells per colon were less in mice receiving Daikenchuto than in mice that received control feed, as both groups received naive CD4+ T cells to induce colitis. Conclusions We demonstrated that feeding administration of Daikenchuto suppresses colitis induced by naive CD4+ T cell transfer into SCID mice. Daikenchuto may show clinical benefit in the treatment of human inflammatory bowel disease and further studies are warranted.

元の言語英語
ページ(範囲)2571-2579
ページ数9
ジャーナルDigestive Diseases and Sciences
57
発行部数10
DOI
出版物ステータス出版済み - 10 1 2012

Fingerprint

SCID Mice
Colitis
T-Lymphocytes
Cytokines
Interleukin-17
Colon
Bacterial Translocation
dai-kenchu-to
Messenger RNA
Gastrointestinal Motility
Herbal Medicine
Inflammatory Bowel Diseases
Real-Time Polymerase Chain Reaction
Flow Cytometry
Body Weight
Inflammation

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

これを引用

Feeding administration of daikenchuto suppresses colitis induced by naive CD4+ T cell transfer into SCID mice. / iwasa, tsutomu; Ogino, Haruei; Nakamura, Kazuhiko; Ihara, Eikichi; Akiho, Hirotada; Takayanagi, Ryoichi.

:: Digestive Diseases and Sciences, 巻 57, 番号 10, 01.10.2012, p. 2571-2579.

研究成果: ジャーナルへの寄稿記事

iwasa, tsutomu ; Ogino, Haruei ; Nakamura, Kazuhiko ; Ihara, Eikichi ; Akiho, Hirotada ; Takayanagi, Ryoichi. / Feeding administration of daikenchuto suppresses colitis induced by naive CD4+ T cell transfer into SCID mice. :: Digestive Diseases and Sciences. 2012 ; 巻 57, 番号 10. pp. 2571-2579.
@article{0ed9634e2c1344e990daf7d159388a8f,
title = "Feeding administration of daikenchuto suppresses colitis induced by naive CD4+ T cell transfer into SCID mice",
abstract = "Background and Aims Daikenchuto, a traditional Japanese herbal medicine, suppresses bacterial translocation by improvement of gastrointestinal motility and blood flow. As Daikenchuto reportedly reduces gastrointestinal inflammatory activity by these mechanisms, we analyzed whether Daikenchuto suppresses experimental colitis and reduces inflammatory cytokine expression in a mouse model. Methods Colitis was induced by transfer of naive CD4+ T cells of BALB/c mice into SCID mice, and mice were given either control or 2.7 {\%} Daikenchuto-containing feed. We investigated body weight, clinical symptoms, histological changes, and Th1- and Th17-cytokine expression. Cytokine mRNA expression was analyzed using real-time RT-PCR. The ratio of IL-17+ and IFN-c+ CD4+ T cells were analyzed by flow cytometry. Results Daikenchuto delayed the development of colitis and significantly reduced the histological inflammation scores. Analyses of cytokine mRNA revealed that Th17 cytokines were significantly decreased in colons of mice that received Daikenchuto. Absolute numbers of IL-17+ or IFN-c+ CD4+ T cells per colon were less in mice receiving Daikenchuto than in mice that received control feed, as both groups received naive CD4+ T cells to induce colitis. Conclusions We demonstrated that feeding administration of Daikenchuto suppresses colitis induced by naive CD4+ T cell transfer into SCID mice. Daikenchuto may show clinical benefit in the treatment of human inflammatory bowel disease and further studies are warranted.",
author = "tsutomu iwasa and Haruei Ogino and Kazuhiko Nakamura and Eikichi Ihara and Hirotada Akiho and Ryoichi Takayanagi",
year = "2012",
month = "10",
day = "1",
doi = "10.1007/s10620-012-2218-0",
language = "English",
volume = "57",
pages = "2571--2579",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Feeding administration of daikenchuto suppresses colitis induced by naive CD4+ T cell transfer into SCID mice

AU - iwasa, tsutomu

AU - Ogino, Haruei

AU - Nakamura, Kazuhiko

AU - Ihara, Eikichi

AU - Akiho, Hirotada

AU - Takayanagi, Ryoichi

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Background and Aims Daikenchuto, a traditional Japanese herbal medicine, suppresses bacterial translocation by improvement of gastrointestinal motility and blood flow. As Daikenchuto reportedly reduces gastrointestinal inflammatory activity by these mechanisms, we analyzed whether Daikenchuto suppresses experimental colitis and reduces inflammatory cytokine expression in a mouse model. Methods Colitis was induced by transfer of naive CD4+ T cells of BALB/c mice into SCID mice, and mice were given either control or 2.7 % Daikenchuto-containing feed. We investigated body weight, clinical symptoms, histological changes, and Th1- and Th17-cytokine expression. Cytokine mRNA expression was analyzed using real-time RT-PCR. The ratio of IL-17+ and IFN-c+ CD4+ T cells were analyzed by flow cytometry. Results Daikenchuto delayed the development of colitis and significantly reduced the histological inflammation scores. Analyses of cytokine mRNA revealed that Th17 cytokines were significantly decreased in colons of mice that received Daikenchuto. Absolute numbers of IL-17+ or IFN-c+ CD4+ T cells per colon were less in mice receiving Daikenchuto than in mice that received control feed, as both groups received naive CD4+ T cells to induce colitis. Conclusions We demonstrated that feeding administration of Daikenchuto suppresses colitis induced by naive CD4+ T cell transfer into SCID mice. Daikenchuto may show clinical benefit in the treatment of human inflammatory bowel disease and further studies are warranted.

AB - Background and Aims Daikenchuto, a traditional Japanese herbal medicine, suppresses bacterial translocation by improvement of gastrointestinal motility and blood flow. As Daikenchuto reportedly reduces gastrointestinal inflammatory activity by these mechanisms, we analyzed whether Daikenchuto suppresses experimental colitis and reduces inflammatory cytokine expression in a mouse model. Methods Colitis was induced by transfer of naive CD4+ T cells of BALB/c mice into SCID mice, and mice were given either control or 2.7 % Daikenchuto-containing feed. We investigated body weight, clinical symptoms, histological changes, and Th1- and Th17-cytokine expression. Cytokine mRNA expression was analyzed using real-time RT-PCR. The ratio of IL-17+ and IFN-c+ CD4+ T cells were analyzed by flow cytometry. Results Daikenchuto delayed the development of colitis and significantly reduced the histological inflammation scores. Analyses of cytokine mRNA revealed that Th17 cytokines were significantly decreased in colons of mice that received Daikenchuto. Absolute numbers of IL-17+ or IFN-c+ CD4+ T cells per colon were less in mice receiving Daikenchuto than in mice that received control feed, as both groups received naive CD4+ T cells to induce colitis. Conclusions We demonstrated that feeding administration of Daikenchuto suppresses colitis induced by naive CD4+ T cell transfer into SCID mice. Daikenchuto may show clinical benefit in the treatment of human inflammatory bowel disease and further studies are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84867846380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867846380&partnerID=8YFLogxK

U2 - 10.1007/s10620-012-2218-0

DO - 10.1007/s10620-012-2218-0

M3 - Article

VL - 57

SP - 2571

EP - 2579

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 10

ER -